Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Conmed, Raises Price Target to $106

Needham Maintains Buy on Conmed, Raises Price Target to $106

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $90 to $106.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $90 to $106.

Analyst Ratings

Deutsche Bank Maintains Buy Rating for Honeywell Intl: Here’s What You Need To Know

By Benzinga Insights

April 12, 1:00 PM

Deutsche Bank has decided to maintain its Buy rating of Honeywell Intl (NASDAQ:HON) and lower its price target…

HON

Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry

By Benzinga Insights

June 3, 11:00 AM

In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry…

JNJ

News

ePlus Achieves The AWS Resilience Competency

By Benzinga Newsdesk

November 30, 9:38 AM

ePlus inc. (NASDAQ NGS: PLUS – news) today announced that it has achieved the Amazon Web Services (AWS) Resilience Competency in the Resilience Recovery category. This specialization recognizes ePlus

AMZN

Movers
News

Dell Technologies Stock Is Rising Today: What’s Going On?

By Adam Eckert

June 20, 9:29 AM

Dell Technologies Inc (NYSE:DELL) shares are trading higher Thursday after Elon Musk and Dell CEO Michael Dell announced the company is assembling half of the racks for an xAI supercomputer.

DELL

Needham Maintains Buy on Conmed, Raises Price Target to $106

Related Posts

Deutsche Bank Maintains Buy Rating for Honeywell Intl: Here’s What You Need To Know

Performance Comparison: Johnson & Johnson And Competitors In Pharmaceuticals Industry

ePlus Achieves The AWS Resilience Competency

Dell Technologies Stock Is Rising Today: What’s Going On?